MQPD: An Antioxidant Quinone–Dopamine Hybrid Which Induces Sustained Brain Dopamine Elevation

MQPD: An Antioxidant Quinone–Dopamine Hybrid Which Induces Sustained Brain Dopamine Elevation Научная публикация

Журнал

Antioxidants
ISSN: 2076-3921

Вых. Данные

Год: 2025, Том: 14, Номер: 12, Номер статьи : 1416, Страниц : DOI: 10.3390/antiox14121416

Авторы

Kulikova Olga ¹ , Adaeva Olga ^1,2 , Timoshina Yulia ^1,3 , Abaimov Denis ¹ , Muzychuk Olga ¹ , Nesterov Maxim ⁴ , Lopachev Alexander ^1,5 , Kazanskaya Rogneda ^1,5 , Demchuk Dmitry ² , Semenov Victor ² , Latanov Alexander ^3,6 , Fedorova Tatiana ¹

Организации

1	Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia
2	N. D. Zelinsky Institute of Organic Chemistry RAS, 119991 Moscow, Russia
3	School of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia
4	Bioanalytical Laboratory, Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia, Svetlye Gory Village, Moscow Region, 143442 Krasnogorsk, Russia
5	Institute of Translational Biomedicine, Saint Petersburg State University, 199034 St. Petersburg, Russia
6	Research Institute for Brain Development and Peak Performance, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia

Parkinson’s disease (PD) therapy is challenged by the multifactorial nature of neurodegeneration, necessitating an approach combining dopamine replenishment and combating oxidative stress. This study characterizes the neuroprotective potential of MQPD, a novel hybrid molecule containing dopamine with a quinone fragment structurally analogous to coenzyme Q. We evaluated MQPD’s antioxidant capacity in vitro using DPPH radical scavenging and lipid peroxidation assays, its neuroprotective efficacy against mitochondrial toxins (rotenone, paraquat) in neuronal cultures, and its ability to modulate striatal dopamine levels in mice. MQPD demonstrated significant antioxidant activity, reduced reactive oxygen species, and was more effective than dopamine or L-DOPA in mitigating toxin-induced cell death. While MQPD itself showed low brain bioavailability, its administration resulted in a sustained increase in striatal dopamine levels for up to four days. The results indicate that MQPD is a potent neuroprotective agent whose effects are likely mediated by direct antioxidant activity and a long-acting mechanism that stabilizes tissue dopamine levels, offering a promising alternative to current therapies for PD.

Kulikova O. , Adaeva O. , Timoshina Y. , Abaimov D. , Muzychuk O. , Nesterov M. , Lopachev A. , Kazanskaya R. , Demchuk D. , Semenov V. , Latanov A. , Fedorova T.
MQPD: An Antioxidant Quinone–Dopamine Hybrid Which Induces Sustained Brain Dopamine Elevation
Antioxidants. 2025. V.14. N12. 1416 . DOI: 10.3390/antiox14121416 WOS Scopus OpenAlex

Web of science:	WOS:001646072700001
Scopus:	2-s2.0-105025821117
OpenAlex:	W7106786310

БД	Цитирований
Scopus	Нет цитирований